AC
RPTX

Athanor Capital’s Repare Therapeutics RPTX Stock Holding History

Athanor Capital’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,623
Closed -$234K – 709
2021
Q1 		$234K Sell
7,623
-14,078
-65% -$478K 0.01% 653
2020
Q4 		$744K Buy
+21,701
New +$648K 0.02% 379

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Athanor Capital's RPTX Position: Q2 2021 in Review

Athanor Capital sold out of Repare Therapeutics (RPTX) in Q2 2021, closing a stake of 7,623 shares — an estimated $234K sold.

Athanor Capital first reported a position in RPTX in Q4 2020 and held it in 2 quarters. The position peaked at $744K in Q4 2020. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2021.

  • Athanor Capital reported no remaining Repare Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 7,623 Repare Therapeutics shares in Q2 2021, an estimated $234K.
  • Athanor Capital first reported a position in Repare Therapeutics in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's Repare Therapeutics position peaked at $744K in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.